Vaccination with Heat-killed Leishmania Antigen or Recombinant Leishmanial Protein and CpG Oligodeoxynucleotides Induces Long-Term Memory CD4+and CD8+T Cell Responses and Protection Against Leishmania major Infection
Open Access
- 10 June 2002
- journal article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 195 (12) , 1565-1573
- https://doi.org/10.1084/jem.20020147
Abstract
CpG oligodeoxynucleotides (ODN) have potent effects on innate and adaptive cellular immune responses. In this report, the ability of CpG ODN to confer long-term immunity and protection when used as a vaccine adjuvant with a clinical grade of leishmanial antigen, autoclaved Leishmania major (ALM), or a recombinant leishmanial protein was studied. In two different mouse models of L. major infection, vaccination with ALM plus CpG ODN was able to control infection and markedly reduce lesion development in susceptible BALB/c and resistant C57BL/6 (B6) mice, respectively, up to 12 wk after immunization. Moreover, B6 mice immunized with ALM plus CpG ODNs were still protected against infectious challenge even 6 mo after vaccination. In terms of immune correlates of protection, ALM plus CpG ODN-vaccinated mice displayed L. major–specific T helper cell 1 and CD8+ responses. In addition, complete protection was markedly abrogated in mice depleted of CD8+ T cells at the time of vaccination. Similarly, mice vaccinated with a recombinant leishmanial protein plus CpG ODN also had long-term protection that was dependent on CD8+ T cells in vivo. Together, these data demonstrate that CpG ODN, when used as a vaccine adjuvant with either a recombinant protein or heat-killed leishmanial antigen, can induce long-term protection against an intracellular infection in a CD8-dependent manner.Keywords
This publication has 40 references indexed in Scilit:
- Immunization with a Polyprotein Vaccine Consisting of the T-Cell Antigens Thiol-Specific Antioxidant,Leishmania majorStress-Inducible Protein 1, andLeishmaniaElongation Initiation Factor Protects against LeishmaniasisInfection and Immunity, 2002
- Protection against Cutaneous Leishmaniasis Induced by Recombinant Antigens in Murine and Nonhuman Primate Models of the Human DiseaseInfection and Immunity, 2001
- Vaccine requirements for sustained cellular immunity to an intracellular parasitic infectionNature Medicine, 1998
- IL-4 Rapidly Produced by Vβ4 Vα8 CD4+ T Cells Instructs Th2 Development and Susceptibility to Leishmania major in BALB/c MicePublished by Elsevier ,1997
- Resistance to Leishmania major Induced by Tolerance to a Single AntigenScience, 1996
- Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene ImmunizationScience, 1996
- The Adjuvant Effect of Interleukin-12 in a Vaccine Against Leishmania majorScience, 1994
- Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response.The Journal of Experimental Medicine, 1993
- Recombinant interleukin 12 cures mice infected with Leishmania major.The Journal of Experimental Medicine, 1993
- Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism.The Journal of Experimental Medicine, 1990